Genetic Technologies Limited
NASDAQ: GENE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Kevin Camilleri
- Employees
- 55
- Headquarters
- Fitzroy, Australia
- IPO year
- 2005
- Market cap
- $111.2M
- Website
- https://www.gtglabs.com
Loading GENE…
Loading profile data…Frequently asked questions about GENE
What does Genetic Technologies Limited (GENE) do?
Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment...
Where does GENE trade?
Genetic Technologies Limited (GENE) trades on the NASDAQ Capital Market.
What sector is GENE in?
Genetic Technologies Limited (GENE) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Genetic Technologies Limited?
Kevin Camilleri is the chief executive officer of Genetic Technologies Limited (GENE).
Where is Genetic Technologies Limited headquartered?
Genetic Technologies Limited is headquartered in Australia.
Does GENE pay a dividend?
Genetic Technologies Limited (GENE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GENE go public?
Genetic Technologies Limited (GENE) completed its initial public offering in 2005.
Is GENE an ADR?
Yes — GENE is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Genetic Technologies Limited reporting and dividends follow the underlying issuer.